Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 2/2017

17.03.2017 | SCLC | zertifizierte fortbildung

Diagnostik und Therapie

Evidenzbasiertes Vorgehen beim kleinzelligen Lungenkarzinom

verfasst von: Sacha Rothschild, Alexandros Papachristofilou, Catherine Schill El Mekabaty, Prof. Dr. med. Frank Zimmermann

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapieoptionen für Lungenkrebspatienten haben in den vergangenen Jahren deutlich zugenommen. Allerdings gilt dies in erster Linie für nichtkleinzellige Karzinome. Die Möglichkeiten zur Behandlung von Patienten mit kleinzelligem Lungenkarzinom sind nach wie vor begrenzt.
Literatur
1.
3.
Zurück zum Zitat Dela Cruz CS et al. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.CrossRef Dela Cruz CS et al. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.CrossRef
5.
Zurück zum Zitat Govindan R et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.CrossRefPubMed Govindan R et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539–44.CrossRefPubMed
7.
8.
Zurück zum Zitat Lu YY et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35(7):697–703.CrossRefPubMed Lu YY et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35(7):697–703.CrossRefPubMed
9.
Zurück zum Zitat Micke P et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer. 2002;37(3):271–6.CrossRefPubMed Micke P et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer. 2002;37(3):271–6.CrossRefPubMed
10.
Zurück zum Zitat Yu JB et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol. 2010;5(2):215–9.CrossRefPubMed Yu JB et al. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol. 2010;5(2):215–9.CrossRefPubMed
11.
Zurück zum Zitat Schreiber D et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350–7.CrossRefPubMed Schreiber D et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer. 2010;116(5):1350–7.CrossRefPubMed
12.
Zurück zum Zitat Rami-Porta R et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Jan 31. [Epub ahead of print]. Rami-Porta R et al. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Jan 31. [Epub ahead of print].
13.
Zurück zum Zitat Wong AT et al. Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database. J Thorac Oncol. 2016;11(2):242–8.CrossRefPubMed Wong AT et al. Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database. J Thorac Oncol. 2016;11(2):242–8.CrossRefPubMed
14.
Zurück zum Zitat Altorki NK et al. Anatomical segmentectomy and wedge resections are associated with comparable outcomes for patients with small cT1N0 non-small cell lung cancer. J Thorac Oncol. 2016;11(11):1984–92.CrossRefPubMed Altorki NK et al. Anatomical segmentectomy and wedge resections are associated with comparable outcomes for patients with small cT1N0 non-small cell lung cancer. J Thorac Oncol. 2016;11(11):1984–92.CrossRefPubMed
15.
Zurück zum Zitat Takada M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054–60.CrossRefPubMed Takada M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054–60.CrossRefPubMed
16.
Zurück zum Zitat Kubota K et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy: a randomized phase 3 study. Lancet Oncol. 2014;15(1):106–13.CrossRefPubMed Kubota K et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy: a randomized phase 3 study. Lancet Oncol. 2014;15(1):106–13.CrossRefPubMed
17.
Zurück zum Zitat Rossi A et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.CrossRefPubMed Rossi A et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.CrossRefPubMed
18.
Zurück zum Zitat Rossi A et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010;70(2):119–28.CrossRefPubMed Rossi A et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer. 2010;70(2):119–28.CrossRefPubMed
19.
Zurück zum Zitat Wolfson AH et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84.CrossRefPubMed Wolfson AH et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84.CrossRefPubMed
20.
Zurück zum Zitat Foster NR et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011;117(6):1262–71.CrossRefPubMed Foster NR et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011;117(6):1262–71.CrossRefPubMed
21.
Zurück zum Zitat Mahmoud O et al. Intrathoracic extensive-stage small cell lung cancer. Int J Clin Oncol. 2016;21(6):1062–1070.CrossRefPubMed Mahmoud O et al. Intrathoracic extensive-stage small cell lung cancer. Int J Clin Oncol. 2016;21(6):1062–1070.CrossRefPubMed
22.
Zurück zum Zitat Jeremic B et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17(7):2092–9.CrossRefPubMed Jeremic B et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17(7):2092–9.CrossRefPubMed
23.
Zurück zum Zitat Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet. 2015;385(9962):36–42.CrossRefPubMed Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet. 2015;385(9962):36–42.CrossRefPubMed
24.
Zurück zum Zitat Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–5.CrossRefPubMed Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–5.CrossRefPubMed
25.
Zurück zum Zitat Pignon JP et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–24.CrossRefPubMed Pignon JP et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–24.CrossRefPubMed
26.
Zurück zum Zitat Fried DB et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837–45.CrossRefPubMed Fried DB et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837–45.CrossRefPubMed
27.
Zurück zum Zitat De Ruysscher D et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24(7):1057–63.CrossRefPubMed De Ruysscher D et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24(7):1057–63.CrossRefPubMed
28.
Zurück zum Zitat Wong AT et al. Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma. Clin Lung Cancer. 2016 Aug 8. [Epub ahead of print]. Wong AT et al. Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma. Clin Lung Cancer. 2016 Aug 8. [Epub ahead of print].
29.
Zurück zum Zitat Slotman B. What is the optimal radiotherapy schedule for limited stage small cell lung cancer? Lung Cancer. 2017;105:52–53.CrossRefPubMed Slotman B. What is the optimal radiotherapy schedule for limited stage small cell lung cancer? Lung Cancer. 2017;105:52–53.CrossRefPubMed
30.
Zurück zum Zitat Woolf DK et al. The current role of radiotherapy in the treatment of small cell lung cancer. Clin Oncol (R Coll Radiol). 2016;28(11):712–19.CrossRef Woolf DK et al. The current role of radiotherapy in the treatment of small cell lung cancer. Clin Oncol (R Coll Radiol). 2016;28(11):712–19.CrossRef
31.
Zurück zum Zitat Cai S et al. Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy. Radiat Oncol. 2014;9:17.CrossRefPubMedPubMedCentral Cai S et al. Feasibility of omitting clinical target volume for limited-disease small cell lung cancer treated with chemotherapy and intensity-modulated radiotherapy. Radiat Oncol. 2014;9:17.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Hügli A et al. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d’Oncologie Thoracique des Régions Alpines. J Clin Oncol. 2000;18(8):1662–7.CrossRefPubMed Hügli A et al. Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d’Oncologie Thoracique des Régions Alpines. J Clin Oncol. 2000;18(8):1662–7.CrossRefPubMed
33.
Zurück zum Zitat Bogart JA et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59(2):460–8.CrossRefPubMed Bogart JA et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys. 2004;59(2):460–8.CrossRefPubMed
34.
Zurück zum Zitat Komaki R et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005;62(2):342–50.CrossRefPubMed Komaki R et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005;62(2):342–50.CrossRefPubMed
35.
Zurück zum Zitat Turrisi AT 3rd et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.CrossRefPubMed Turrisi AT 3rd et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.CrossRefPubMed
36.
Zurück zum Zitat Bayman NA et al. Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer. 2009;63(3):307–14.CrossRefPubMed Bayman NA et al. Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer. 2009;63(3):307–14.CrossRefPubMed
37.
Zurück zum Zitat Faivre-Finn C et al. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open. 2016;6(1):e009849.CrossRefPubMedPubMedCentral Faivre-Finn C et al. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. BMJ Open. 2016;6(1):e009849.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Salama JK et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043–9.CrossRefPubMed Salama JK et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. J Thorac Oncol. 2013;8(8):1043–9.CrossRefPubMed
39.
Zurück zum Zitat Seto T et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol. 2014;32(Suppl 5s):Abstr 7503. Seto T et al. Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. J Clin Oncol. 2014;32(Suppl 5s):Abstr 7503.
41.
Zurück zum Zitat Postmus PE et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409–11.CrossRefPubMed Postmus PE et al. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23(9):1409–11.CrossRefPubMed
42.
Zurück zum Zitat Giaccone G et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23(11):1697–9.CrossRefPubMed Giaccone G et al. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23(11):1697–9.CrossRefPubMed
43.
Zurück zum Zitat von Pawel J et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67.CrossRef von Pawel J et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67.CrossRef
44.
Zurück zum Zitat Hagmann R et al. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015;6(11):1148–54.CrossRefPubMedPubMedCentral Hagmann R et al. Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. J Cancer. 2015;6(11):1148–54.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Eckardt JR et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086–92.CrossRefPubMed Eckardt JR et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086–92.CrossRefPubMed
46.
Zurück zum Zitat Rudin CM et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42–51.CrossRefPubMed Rudin CM et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42–51.CrossRefPubMed
47.
Zurück zum Zitat Reck M et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013; 24(1):75–83.CrossRefPubMed Reck M et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013; 24(1):75–83.CrossRefPubMed
Metadaten
Titel
Diagnostik und Therapie
Evidenzbasiertes Vorgehen beim kleinzelligen Lungenkarzinom
verfasst von
Sacha Rothschild
Alexandros Papachristofilou
Catherine Schill El Mekabaty
Prof. Dr. med. Frank Zimmermann
Publikationsdatum
17.03.2017
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 2/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-017-5558-2

Weitere Artikel der Ausgabe 2/2017

InFo Hämatologie + Onkologie 2/2017 Zur Ausgabe

neues aus der forschung

Frühes Hinschauen lohnt sich